ConductScience.org, home

Paper1596567

Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.

Berman E and 1 other. Blood, 1992. Cited by 175 papers, by iCite.

Cite this record

ConductScience Library. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Papers, record 1596567. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1596567

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.
PubMed
Journal
Blood
PubMed
Year
1992
PubMed
Publication types
Comparative Study, Journal Article
PubMed
Citations, by iCite
175
iCite
Relative citation ratio, by iCite
6.04
iCite
Revised in PubMed
2021-02-16
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Berman EE
2McBride MM

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DaunorubicinMajor topic
Drug ResistanceMajor topic
IdarubicinMajor topic
Leukemia, Myeloid, AcuteMajor topic
Precursor Cell Lymphoblastic Leukemia-LymphomaMajor topic
Cell Division
Humans
Tumor Cells, Cultured
Verapamil

Source PubMed

Download CSV of topics

Cited by34

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 175 citations.

PMIDTitleJournalYearIn PapersSource
39833882The clinical observation of none-promyelocytic AML patients inducted with idarubicin or daunorubicin included standard regimens: a tertiary care center experience.BMC Pharmacol Toxicol2025https://conductscience.org/library/papers/39833882PubMed
325660262-Deoxy-D-glucose enhances the anti-cancer effects of idarubicin on idarubicin-resistant P388 leukemia cells.Oncol Lett2020https://conductscience.org/library/papers/32566026PubMed
31173485Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experience.Cancer Med2019https://conductscience.org/library/papers/31173485PubMed
30968179Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation.Cancer Chemother Pharmacol2019https://conductscience.org/library/papers/30968179PubMed
26037486The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.Cochrane Database Syst Rev2015https://conductscience.org/library/papers/26037486PubMed
25558979Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies.Pharmacogenomics J2015https://conductscience.org/library/papers/25558979PubMed
22358301ABCB1 genetic variation and P-glycoprotein expression/activity in a cohort of Brazilian acute myeloid leukemia patients.J Cancer Res Clin Oncol2012https://conductscience.org/library/papers/22358301PubMed
19826132Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.J Clin Oncol2009https://conductscience.org/library/papers/19826132PubMed
19767767A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.Acta Pharmacol Sin2009https://conductscience.org/library/papers/19767767PubMed
18769895Recent advances in management of acute myeloid leukemia (AML).Indian J Pediatr2008https://conductscience.org/library/papers/18769895PubMed
17965967The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts.Cell Mol Biol Lett2008https://conductscience.org/library/papers/17965967PubMed
16304570Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.Leukemia2005https://conductscience.org/library/papers/16304570PubMed
16107897Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols.Leukemia2005https://conductscience.org/library/papers/16107897PubMed
12621462High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.Bone Marrow Transplant2003https://conductscience.org/library/papers/12621462PubMed
11243404Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance.Leukemia2001https://conductscience.org/library/papers/11243404PubMed
11237056Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group.Leukemia2001https://conductscience.org/library/papers/11237056PubMed
11187892Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies.Leukemia2000https://conductscience.org/library/papers/11187892PubMed
10874219Effects of 1-methyl-3-propyl-7-butylxanthine (MPBX) on idarubicin-induced antitumor activity and bone marrow suppression.Jpn J Cancer Res2000https://conductscience.org/library/papers/10874219PubMed
10865967P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy.Leukemia2000https://conductscience.org/library/papers/10865967PubMed
10413703Effect of the cytostatic agent idarubicin on fibroblasts of the human Tenon's capsule compared with mitomycin C.Br J Ophthalmol1999https://conductscience.org/library/papers/10413703PubMed

See all 34 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/1596567

GET https://conductscience.org/api/papers/v1/1596567/cited_by?page=2